Skip to main content

Table 2 Univariate and multivariate analyses for overall survival in CRC

From: Identification of an at-risk subpopulation with high immune infiltration based on the peroxisome pathway and TIM3 in colorectal cancer

  Univariate analysis Multivariate analysis
  HR (95% CI) p HR (95% CI) p
Gender
 Female 1    
 Male 1.23 (0.98–1.50) 0.076   
Stage
 I 1   1  
 II 1.70 (0.94–3.10) 0.082 1.45 (0.79–2.66) 0.225
 III 2.34 (1.28–4.25) 0.006 1.74 (0.95–3.21) 0.074
 IV 8.26 (4.50–15.18) < 0.001 6.07 (3.25–11.35) < 0.001
Location
 Left colon, rectum 1    
 Right colon 1.13 (0.90–1.42) 0.304   
Microsatellite
 MSI 1    
 MSS 1.11 (0.78–1.58) 0.566   
CMS
 CMS1 1   1  
 CMS2 0.97 (0.67–1.38) 0.848 0.94 (0.63–1.39) 0.743
 CMS3 0.70 (0.42–1.16) 0.171 0.67 (0.37–1.17) 0.160
 CMS4 1.45 (1.00–2.11) 0.049 1.10 (0.74–1.64) 0.625
 Indeterminate 1.55 (0.98–2.46) 0.064 1.41 (0.87–2.29) 0.159
KRAS status
 Wild-type 1   1  
 Mutated 1.27 (1.01–1.61) 0.043 1.29 (1.00–1.66) 0.048
BRAF status
 Wild-type 1    
 Mutated 1.23 (0.85–1.79) 0.28   
TP53 status
Wild-type 1    
Mutated 1.20 (0.92–1.57)    
CIMP
 Low 1    
 High 1.14 (0.83–1.57)    
Group
 Group I + II 1   1  
 Group III 1.68 (1.30–2.17) < 0.001 1.41 (1.05–1.90) 0.023
 Group IV 1.20 (0.90–1.60) 0.223 1.06 (0.77–1.48) 0.709
  1. GSE39582 and TCGA samples of CRC were pooled for this analysis
  2. Abbreviations: HR hazard ratio